GAM
ABCL icon

GEM Asset Management’s AbCellera Biologics ABCL Stock Holding History

GEM Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$80.6K – 104
2025
Q2 		$80.6K Sell
20,000
-10,000
-33% -$24.9K 0.04% 100
2025
Q1 		$62.7K Buy
+30,000
New +$86K 0.04% 94

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

GEM Asset Management's ABCL Position: Q3 2025 in Review

GEM Asset Management sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 20,000 shares — an estimated $80.6K sold.

GEM Asset Management first reported a position in ABCL in Q1 2025 and held it in 2 quarters. The position peaked at $80.6K in Q2 2025. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • GEM Asset Management reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • GEM Asset Management sold 20,000 AbCellera Biologics shares in Q3 2025, an estimated $80.6K.
  • GEM Asset Management first reported a position in AbCellera Biologics in Q1 2025 and held it in 2 quarters.
  • GEM Asset Management's AbCellera Biologics position peaked at $80.6K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on GEM Asset Management's 13F filing for Q3 2025, filed 30 Oct 2025.